Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

Dragged down by negative returns for shares of Amgen and Nike, the Dow Jones Industrial Average is down Monday morning.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...